Lonsurf

 Generic Name: Trifluridine/Tipiricil

Trifluridine/tipiricil is the generic name for the trade name drug, Lonsurf. In some cases, health care professionals may use the trade name, Lonsurf, when referring to the generic drug name, trifluridine/tipiricil.

Drug Type: Trifluridine/tipiricil is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. pharma consulting companies,This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor. (For more detail, see "How Trifluridine/tipiricil Works" below).

What Trifluridine/tipiricil Is Used For:

• Trifluridine/tipiricil is used to treat metastatic colorectal cancer in patients who have previously been treated with fluoropyrimidine, oxaliplatin, and irinotecan based chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy (if RAS wild type).
• To treat metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.

How Trifluridine/tipiricil Is Given:

• Trifluridine/tipiricil is a tablet that is taken by mouth.
• Take twice a day within one hour of eating your morning and evening meals.
• Take with a glass of water.
• The tablets come in two strengths and you may need to take a combination of the two strengths to get to your specific dose. Follow your instructions carefully.
• Trifluridine/tipiricil is usually taken twice a day on days 1 to 5, and days 8 to 12 of a 28 day cycle.

The amount of trifluridine/tipiricil that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition you have. Your doctor will determine your exact dosage and schedule.

What Is Radicava?

 What Is Radicava?

Radicava (edaravone injection) is an intravenous medication indicated for the treatment of amyotrophic lateral sclerosis (ALS).
What Are Side Effects of Radicava?

Common side effects of Radicava include:

1.     bruising,
2.     gait disturbance,
3.     headache,
4.     skin inflammation or rash,
5.     eczema,
6.     respiratory failure,
7.     respiratory disorder,
8.     oxygen deficiency,
9.     glucose in the urine, and
10.     fungal skin infections (such as ringworm, jock itch, athlete's foot).

Patients whoto are sensitive to sulfites may have an allergic reaction, including anaphylaxis, to Radicava, which contains sodium bisulfite.

Dosage for Radicava

The recommended dosage of Radicava is 60 mg administered as an intravenous infusion over 60 minutes as follows: named patient program Initial treatment cycle: daily dosing for 14 days followed by a 14-day drug-free period. Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods. Radicava may interact with other drugs.

What Drugs, Substances, or Supplements Interact with Radicava?

Tell your doctor all medications and supplements you use.
Radicava During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Radicava; it may harm a fetus. It is unknown if Radicava passes into breast milk. Consult your doctor before breastfeeding.

‘Alunbrig’ – A named patient medicine for NSCLC

Non-small cell lung cancer is a common cancer, accounting for about 80%-85% of all lung cancer cases. It is one of the leading causes of death in the United States. With in-depth research on the reasons behind lung cancer, cell biology has developed small drugs that can interrupt certain gene mutations and treat patients with NSCLC.

According to research, many of the driving factors for this tumor mutation are 10% EFGR mutation, 23% KRAS mutation and 13% ALK mutation. Realize that certain types of mutations will lead to correct handling in the process.

Among various treatments, the FDA expanded its approval for Alunbrig on April 28, 2017. It is a new generation of ALK inhibitors, mainly approved for the treatment of ALK-positive metastatic NSCLC. The drug is effective when crizotinib is ineffective or does not produce a positive reaction.

Oncology supports Alunbrig because half of the 222 patients who used the drug in clinical trials experienced a nearly 30% cancer reduction. It has similar effects on men and women. However, you must pay attention to the following points before taking Alunbrig:

    For men-For men whose partners are in reproductive health, contraceptives should be used during treatment and at least 3 months after taking the last dose.
    For women-Women who are effectively pregnant should take non-hormonal contraceptives during treatment and should continue to take them until the final dose of 4 months.

The Pharmaceuticals consulting services introduced Alunbrig to named patient medicine because it has not been widely used and is named a patient drug.

Access to medicines under Named Patient Program, which are not available in the patient's country.

 In the life of a patient, sometimes doctors will use all the drug treatment options available in their country/region, and they can only choose one method to send the patient abroad, where the latest drugs are available or buy such drugs from the hospital . Countries with such drugs. The simplest and best option is to buy these drugs from real sources.

At the moment the doctor prescribes such drugs, relatives of patients are confused about how and where to buy such drugs. In most cases, patients or their relatives lack knowledge and are busy with their own work, which makes it very difficult for them and patients to succumb to the disease.

In order to purchase these life-saving drugs, the Indian government has established a clause granting the right to use these drugs, which are classified under the "Named Patient Program (NPP)" label. These drugs can be purchased from drug distributors anywhere in the world, but must be approved by the Indian Drug Administration and Customs in advance.

In order to purchase such drugs, we must know the authentic authorized suppliers in the United States or any European country. There must be a suitable company or person who can guide the patient to complete all documentation and logistics. For this, you can rely on a company called ALLEVIARE LIFE SCIENCES PVT. LTD. Have a team of qualified and experienced professionals who can help and guide patients and their relatives in the right way to get this life-saving medicine at your door.

Advance medicinal treatment of Neurological disorder

Disorders occurring in the central and peripheral nervous system comprise of neurological disorders. These disorders include Alzheimer disease, dementias, cerebrovascular disease, Parkinson’s disease, and traumatic disorder. It is assessed that more than 6 million people die because of stroke each year and an astonishing figure of 80% is that from developing and poor countries.

Lack of proper medications and knowledge, in regards, to neurological disorder causes increasing mortality rate every year. Thus, FDA has approved some widely accepted drugs termed to be a named patient medicine, as the medicines are frequently not available in the underdeveloped and developing countries.

Xadago, an orally administered medicine for the patients suffering from Parkinson’s disease is recommended from 100 mg to 50 mg as per the condition of the patient. It inhibits MAO-B activity after hindering the catabolism of dopamine and thus acting as a mechanical obstruct for Parkinson disease.

Also, Banzel, a triazole derivative is an indicative treatment drug for Seizures allied with Lennox Gastaut syndrome, which is common among children above 4 years and then into adults. The prescribed initial dose per day ranges from 400 mg to 800 mg and a maximum dose of 3200 mg per day. Although the exact mechanism of Banzel is unknown, yet the rufinamide modulates the activity of sodium channels which, in turn, slows down the seizures and its aligned symptoms.

The pharmaceutical consulting services allow the neurology department and its named patient program to export these medicines worldwide, with all its approvals and advancement to cure the fatal diseases like Parkinson and Lennox Gastaut syndrome.

Genetic Named patient medicines and treatment

 It is very difficult to manufacture, approve and release all drugs, especially for rare diseases. Patients with rare diseases often suffer from being unable to treat them. However, some drug consulting services (such as AlleviareIndia) provide services to doctors, hospitals, patients, and government hospitals who have designated patient drugs approved by the named patient program. Genetic diseases are such rare diseases, most of which have not been treated or received special treatment. However, by distributing required drugs and FDA-approved drugs, "AlleviareIndia" supports the use of designated patient supplies for treatment. Some of these drugs are discussed below:

    Zavesca Miglustat-used to treat mild to moderate type 1 Gaucher disease. It comes from both parents and is usually found in patients who lack the enzymes naturally present in the body and destroy the chemical substance called glucosylceramide. Therefore, when the enzyme is not produced, glucosylceramide will not be destroyed and cause spleen and liver enlargement, blood diseases and bone diseases. Zavesca Miglustat prevents the body from producing glycosylceramides, thereby minimizing discomfort.
    Elaprase Idursulfase-It can treat Hunter's syndrome that lacks enzymes, usually replaced by Elaprase Idursulfase. The disease never supports any enzyme replacement therapy, so there is no permanent cure.
    Cystine-needed to treat renal cysteine. Cystine reduces the accumulation of cysteine ​​in certain cells, thus delaying the development of renal failure.
    Cerdelga Miglustat-Like Zavesca Miglustat, Cerdelga has the same purpose, but is designated for long-term treatment of adult patients with Gaucher disease type 1.

Hematology treatment through Named Patient Program

 Hematology is the study of analysis, treatment, etiology and prevention of blood-related diseases. Blood-related diseases affect the production of blood cells, red blood cells and white blood cells, plasma, hemoglobin, bone marrow, and spleen, and destroy the blood clotting mechanism. Hematology usually refers to the diagnosis and treatment of malignant and benign diseases of blood and its components. Some serious fatal diseases that may occur due to blood system diseases are leukemia, myeloma and lymphoma, and these patients require advanced chemotherapy.

Available treatments also include blood coagulation therapy, blood transfusion and drug therapy. The first two are necessary when there is no response to drug treatment or the disease is relieved from the initial stage. However, why wait for more serious conditions to spend higher treatment costs.

Alleviare Life Sciences and pharmaceutical consulting companies provide Delhi hematological malignancies with patient medicines at a cheaper price. All these drugs have been standardized and approved by the Medical Association. Alleviare Life Sciences’ designated patient supplies provide designated patient drugs such as MabCampth to treat B-cell chronic lymphocytic leukemia (B-CLL), which is a type of leukocyte cancer called B-lymphocytes and Normosang. Treatment of sudden onset of porphyria in patients with acute hepatitis.

There are many other named patient drugs on the market, such as Eltromobopag for the treatment of chronic immune thrombocytopenia, and Ibrutinib for the treatment of mantle cell lymphoma. Alleviare Life Sciences provides cancer treatment drugs on time throughout the world. These drugs are available on valid prescriptions from clinicians and can only be imported with permission.